Topical antibacterial therapy for acne vulgaris

被引:67
作者
Dreno, B [1 ]
机构
[1] Hop Hotel Dieu, Dept Dermatol, F-44093 Nantes 1, France
关键词
D O I
10.2165/00003495-200464210-00002
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Topical antibiotics and benzoyl peroxide, are the two main topical antibacterial treatments indicated for mild-to-moderate acne vulgaris. Topical antibiotics act both as antibacterial agents suppressing Propionibacterium acnes in the sebaceous follicle and as anti-inflammatory agents. Benzoyl peroxide is a powerful antimicrobial agent that rapidly destroys both bacterial organisms and yeasts. Topical clindamycin and erythromycin have been proven to be effective against inflammatory acne vulgaris in concentrations of 1-4% with or without the addition of zinc. However, none of the antibacterials tested was more effective than benzoyl peroxide, which also has the advantage of not being associated with antimicrobial resistance. Topical antibacterial therapy should be discontinued once improvement is observed. If no improvement is observed within 6-8 weeks, the agent should be discontinued and a therapeutic switch considered. The primary limitation of benzoyl peroxide for some acne vulgaris patients is cutaneous irritation or dryness. Antibacterial therapy can be used in combination with other agents. Combining topical antibiotics and topical retinoids may enhance the efficacy, since the retinoid will improve the penetration of the antibiotic. Combining a topical antibiotic with benzoyl peroxide may increase the bactericidal effect of the antibiotic and reduce the potential for bacterial resistance. Topical and oral antibacterials should not be used in combination for the treatment of acne vulgaris, since this association may increase the risk of bacterial resistance.
引用
收藏
页码:2389 / 2397
页数:9
相关论文
共 55 条
[11]   ERYTHROMYCIN RESISTANT PROPIONIBACTERIA IN ANTIBIOTIC TREATED ACNE PATIENTS - ASSOCIATION WITH THERAPEUTIC FAILURE [J].
EADY, EA ;
COVE, JH ;
HOLLAND, KT ;
CUNLIFFE, WJ .
BRITISH JOURNAL OF DERMATOLOGY, 1989, 121 (01) :51-57
[12]  
EADY EA, 2005, J INVEST DERMATOL, V65, P382
[13]  
EADY EA, 1990, J DERMATOL TREAT, V1, P215, DOI DOI 10.3109/09546639009086737
[14]  
Ellis CN, 2001, CUTIS, V67, P13
[15]   TOPICAL ERYTHROMYCIN WITH ZINC IN ACNE - A DOUBLE-BLIND CONTROLLED-STUDY [J].
FEUCHT, CL ;
ALLEN, BS ;
CHALKER, DK ;
SMITH, JG .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1980, 3 (05) :483-491
[16]  
FISHER AA, 1983, CUTIS, V32, P415
[17]   Comparative efficacy of clindamycin and benzoyl peroxide for in vivo suppression of Propionibacterium acnes [J].
Gans, EH ;
Kligman, AM .
JOURNAL OF DERMATOLOGICAL TREATMENT, 2002, 13 (03) :107-110
[18]   A placebo-controlled clinical trial to compare a gel containing a combination of isotretinoin (0.05%) and erythromycin (2%) with gels containing isotretinoin (0.05%) or erythromycin (2%) alone in the topical treatment of acne vulgaris [J].
Glass, D ;
Boorman, GC ;
Stables, GI ;
Cunliffe, WJ ;
Goode, K .
DERMATOLOGY, 1999, 199 (03) :242-247
[19]   Topical drug treatment in acne [J].
Gollnick, H ;
Schramm, M .
DERMATOLOGY, 1998, 196 (01) :119-125
[20]   Current concepts of the pathogenesis of acne - Implications for drug treatment [J].
Gollnick, H .
DRUGS, 2003, 63 (15) :1579-1596